CCCC

Over the past six months, C4 Therapeutics experienced several stock events: On September 3, 2026, the company announced it would present new biomarker data on Cemsidomide at the 23rd International Myeloma Society Annual Meeting. An insider planned the sale of common stock on August 14, 2026. On August 11, 2026, the company reported its Second Quarter 2026 Financial Results, with revenue exceeding estimates by 66% and a loss per share improving from the previous year, leading to a +6.9% stock gain. An Inducement Grant was announced on August 10, 2026. On June 12, 2026, C4 Therapeutics presented Phase 1 data at the European Hematology Association 2026 Congress, highlighting Cemsidomide. The stock saw its largest daily move in the past year, increasing by +19.4% on May 29, 2026, and decreased by -13.09% on March 9, 2026.